Antigen-Oligonucleotide Conjugates for Antibody Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack efficiency in identifying and characterizing drug-reactive antibodies (DRAs) or anti-drug antibodies (ADAs), which can inhibit the efficacy of antibody-based therapies, and there is a need for improved techniques to understand and quantify these antibodies for better clinical trials and drug development.
Innovation Solution
The method involves contacting a composition containing antigen binding molecules with an antigen conjugated to a reporter oligonucleotide, isolating the bound molecules using the oligonucleotide, and identifying them to quantify and characterize the antibodies, including using reporter oligonucleotides conjugated to antigens to profile samples from subjects treated with antibody-drug conjugates or therapeutics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to identify drug-reactive antibodies, then the identification process can be performed, but the efficiency and productivity are insufficient
Solution Approach 1:
The patent segments the identification process into distinct functional steps: (1) contacting the antigen binding molecule with the antigen-oligonucleotide conjugate, (2) isolating the bound molecule using the oligonucleotide, and (3) identifying the molecule. This segmentation enables parallel processing and optimization of each step, significantly improving productivity while reducing total identification time.
Solution Approach 2:
The patent introduces an intermediary mechanism using the oligonucleotide as a bridge between the antigen and the detection system. The oligonucleotide facilitates isolation and identification by mediating the binding interaction, allowing for more efficient and rapid detection of drug-reactive antibodies compared to conventional direct detection methods.
2Loss of information
If comprehensive characterization of antibody repertoire is performed, then detailed understanding is achieved, but the complexity of the process increases
Solution Approach 1:
The patent employs a universal detection system where the same antigen-oligonucleotide conjugate can identify different types of antigen binding molecules (monoclonal antibodies, polyclonal antibodies, antibody fragments) across multiple applications. This multi-functionality reduces overall process complexity while maintaining comprehensive characterization capability through a single standardized protocol.
Solution Approach 2:
The patent uses molecular copying through the oligonucleotide probe that creates a detectable copy of the bound antigen binding molecule. This copying mechanism simplifies the detection process by converting complex protein interactions into measurable molecular signals, reducing procedural complexity while preserving complete repertoire information.
3Measurement precision
If quantitative analysis of antibody responses is performed, then precise measurement is achieved, but the difficulty of detection and measurement increases
Solution Approach 1:
The patent incorporates detectable labels (such as fluorescent or enzymatic tags) on the oligonucleotide that produce measurable signals upon binding. These color or signal changes enable precise quantitative analysis of antibody responses through straightforward signal intensity measurement, dramatically reducing the difficulty of detection while maintaining high measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient identification and quantification of drug-reactive antibodies, monitoring responses, and determining immune diversity, thereby aiding in the validation of antibody therapeutics and guiding drug development by assessing immune responses to antibody-based drugs.
Implementation Method 1
contacting a composition including at least one antigen binding molecule with an antigen conjugated to a reporter oligonucleotide; isolating said antigen binding molecule bound to said antigen at least by using said oligonucleotide
Data Source
AI summary
Provided herein are methods for identification of antigen binding molecules such as antibodies from a sample by exposing the antigen binding molecules to an antigen conjugated to an oligonucleotide.